Study Investigating Efficacy of an Occluding Dentifrice for Dentine Hypersensitivity

Dentin Sensitivity Clinical Trial

Official title:

Short Term Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02705716
• Other study ID #: 205212
• Status: Completed
• Phase: N/A
• First received: March 7, 2016
• Last updated: April 19, 2017
• Start date: March 1, 2016
• Est. completion date: May 20, 2016

Study information

• Verified date: April 2017
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will investigate the efficacy of an experimental dentifrice containing 0.454% weight/weight (w/w) stannous fluoride in relieving dentine hypersensitivity (DH) after twice daily brushing, over a 2 week treatment period compared with a standard fluoride dentifrice.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 409
• Est. completion date: May 20, 2016
• Est. primary completion date: May 20, 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Demonstrates understanding of the study procedures, restrictions and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form.

• Participant is male or female aged between 18 and 65 years inclusive.

• Good general and mental health with, in the opinion of the investigator or medically qualified designee.

• No clinically significant and relevant abnormalities in medical history or upon oral examination.

• Absence of any condition that would impact on the participant's safety or well being or affect the individual's ability to understand and follow study procedures and requirements.

• Self-reported history of dentinal hypersensitivity (DH) lasting more than(>) six months but not > 10 years.

• Good general oral health, with a minimum of 20 natural teeth.

• Minimum of 2 accessible non-adjacent teeth (incisors, canines, pre-molars), preferably in different quadrants at screening and minimum of two, non-adjacent accessible teeth (incisors, canines, pre-molars) at baseline.

Exclusion Criteria:

• Women who are pregnant or breast-feeding .

• Daily doses of medication/treatments which, in the opinion of the Investigator, could interfere with the perception of pain. Examples of such medications include analgesics, anticonvulsants, antihistamines that cause marked or moderate sedation, sedatives, tranquilisers, anti-depressants, mood-altering and anti-inflammatory drugs.

• Currently taking antibiotics or has taken antibiotics within two weeks of Baseline.

• Daily dose of a medication which, in the opinion of the investigator, is causing xerostomia.

• Presence of kidney disease, hyperoxaluria, or any other condition that may be exacerbated by oxalic acid or oxalate salts.

• Presence of chronic debilitating disease which, in the opinion of the investigator, could affect study outcomes.

• Any condition which, in the opinion of the investigator, causes xerostomia.

• Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.

• Participation in another clinical study (including cosmetic studies) or receipt of an investigational drug within 30 days of the screening visit.

• Previous participation in this study.

• Recent history (within the last year) of alcohol or other substance abuse.

• Dental prophylaxis within four weeks of Screening, tongue or lip piercing or presence of dental implants.

• Desensitizing treatment within eight weeks of Screening (professional sensitivity treatments and non-toothpaste sensitivity treatments).

• Gross periodontal disease, treatment of periodontal disease (including surgery) within 12 months of Screening, scaling or root planning within 3 months of Screening.

• Teeth bleaching within eight weeks of Screening.

• Tooth with evidence of current or recent caries, or reported treatment of decay within 12 months of Screening.

• Tooth with exposed dentine but with deep, defective or facial restorations, teeth used as abutments for fixed or removable partial dentures, teeth with full crowns or veneers, orthodontic bands or cracked enamel. Sensitive teeth with contributing aetiologies other than erosion, abrasion or recession of exposed dentine.

• Sensitive tooth not expected to respond to treatment with an over-the-counter toothpaste in the opinion of the Investigator.

• Use of an oral care product indicated for the relief of dentine hypersensitivity within eight weeks of screening.

• Individuals who require antibiotic prophylaxis for dental procedures.

• Any participant who, in the judgment of the investigator, should not participate in the study.

Related Conditions & MeSH terms

• Dentin Sensitivity
• Hypersensitivity

Intervention

Other:
• 0.454% w/w stannous fluoride (1100ppm fluoride)
Dentifrice containing 0.454% w/w stannous fluoride (1100ppm fluoride)
• 0.76% sodium monofluorophosphate (1000ppm fluoride)
Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)

Locations

Country	Name	City	State
United Kingdom	GSK Investigational Site	Ellesmere Port	Cheshire
United Kingdom	GSK Investigational Site	Manchester
United Kingdom	GSK Investigational Site	Wirral

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Schiff Sensitivity Score on Day 14	Schiff sensitivity score was assessed by examiner as participant's response to an evaporative (air) stimulus after the stimulation of each individual tooth. Response of participant was scored using Schiff sensitivity scale range of 0-3; 0=Participant does not respond to air stimulation; 1=Participant responds to air stimulus but does not request discontinuation of stimulus; 2=Participant responds to air stimulus and requests discontinuation or moves from stimulus; 3= Participant responds to stimulus, considers stimulus to be painful, and requests discontinuation of the stimulus. A reduction in Schiff Sensitivity score indicates improvement in sensitivity.	Baseline, Day 14
Secondary	Change From Baseline in Schiff Sensitivity Score on Day 7	Schiff sensitivity score was assessed by examiner as participant's response to an evaporative (air) stimulus after the stimulation of each individual tooth. Response of participant was scored using Schiff sensitivity scale range of 0-3; 0=Participant does not respond to air stimulation; 1=Participant responds to air stimulus but does not request discontinuation of stimulus; 2=Participant responds to air stimulus and requests discontinuation or moves from stimulus; 3= Participant responds to stimulus, considers stimulus to be painful, and requests discontinuation of the stimulus. A reduction in Schiff Sensitivity score indicates improvement in sensitivity.	Baseline, Day 7
Secondary	Change From Baseline in Tactile Threshold on Day 7 and 14	Tactile threshold was assessed by examiner using a constant pressure probe (Yeaple probe) which allowed application of a known force to the dentin surface from 10 g to an upper threshold of 80g in increments of 10 g. The tactile threshold is the maximum pressure applied at which participant do not report any pain or discomfort. The tactile threshold for each tooth was determined by asking the participant whether the sensation caused discomfort. The pressure setting at which the participant gave two consecutive 'yes' responses was recorded as the tactile threshold. The higher the tactile threshold, the less sensitive the tooth.	Baseline, Day 7 and Day 14